Future of automated insulin delivery systems

Jessica Castle, J. Hans DeVries, Boris Kovatchev

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.

Original languageEnglish (US)
Pages (from-to)S67-S72
JournalDiabetes Technology and Therapeutics
Volume19
DOIs
StatePublished - Jun 1 2017

Fingerprint

Insulin
Glucose
Drug Approval
Automation
United States Food and Drug Administration
Type 1 Diabetes Mellitus
Hormones
Equipment and Supplies

Keywords

  • Artificial pancreas
  • Continuous glucose monitoring
  • Type 1 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Cite this

Future of automated insulin delivery systems. / Castle, Jessica; DeVries, J. Hans; Kovatchev, Boris.

In: Diabetes Technology and Therapeutics, Vol. 19, 01.06.2017, p. S67-S72.

Research output: Contribution to journalArticle

Castle, Jessica ; DeVries, J. Hans ; Kovatchev, Boris. / Future of automated insulin delivery systems. In: Diabetes Technology and Therapeutics. 2017 ; Vol. 19. pp. S67-S72.
@article{83816df420244e079672c3357b2f5aa6,
title = "Future of automated insulin delivery systems",
abstract = "Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.",
keywords = "Artificial pancreas, Continuous glucose monitoring, Type 1 diabetes",
author = "Jessica Castle and DeVries, {J. Hans} and Boris Kovatchev",
year = "2017",
month = "6",
day = "1",
doi = "10.1089/dia.2017.0012",
language = "English (US)",
volume = "19",
pages = "S67--S72",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",

}

TY - JOUR

T1 - Future of automated insulin delivery systems

AU - Castle, Jessica

AU - DeVries, J. Hans

AU - Kovatchev, Boris

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.

AB - Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.

KW - Artificial pancreas

KW - Continuous glucose monitoring

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85020455289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020455289&partnerID=8YFLogxK

U2 - 10.1089/dia.2017.0012

DO - 10.1089/dia.2017.0012

M3 - Article

VL - 19

SP - S67-S72

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

SN - 1520-9156

ER -